Jim Miller - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Jim Miller


Jim Miller Pharmtech contributing editor and EAB member

Jim Miller
President, PharmSource Information Services,
Bio/Pharmaceutical Outsourcing Report

PharmTech Contributing editor, Outsourcing Outlook

Jim Miller is the founder and president of PharmSource. A preeminent expert in bio/pharmaceutical outsourcing, Jim established and presides over the pharmaceutical industry’s principal source of market intelligence on the business of contract research, development and manufacturing of bio/pharmaceuticals. PharmSource’s subscription databases, reports and consulting services are used by major pharmaceutical companies, contract manufacturers and contract research organizations to understand key market trends, identify new business opportunities and establish effective business and sourcing strategies. Jim writes regular columns on outsourcing for Pharmaceutical Technology, Pharmaceutical Technology Europe, and BioPharm magazines.

Jim’s other career highlights include a stint as president and chief operating officer of St. Anthony Publishing, a pioneering provider of value-added information services to hospitals and physician practices. He was a consultant in corporate strategy with the Boston Consulting Group, a project economist for the World Bank, and a Peace Corps volunteer in Botswana. He holds an MBA degree from the Stanford University Graduate School of Business.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
35%
Breakthrough designations
12%
Protecting the supply chain
35%
Expedited reviews of drug submissions
12%
More stakeholder involvement
6%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges

Click here